This may suggest that while CDK4/6 treatment tumours may show differential pathway activation and sensitivity to monotherapy treatments, combinations such as capivasertib and fulvestrant can be effective even without the same impact on cell cycle pathways, possibly as a result of targeting other critical cellular processes. Here, CDK4 is linked to neoplasm.